MARKET

ARAV

ARAV

Aravive Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.70
+0.23
+3.49%
Opening 13:41 11/19 EST
OPEN
6.60
PREV CLOSE
6.47
HIGH
6.70
LOW
6.47
VOLUME
4.42K
TURNOVER
--
52 WEEK HIGH
9.72
52 WEEK LOW
3.070
MARKET CAP
75.75M
P/E (TTM)
-1.1164
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARAV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARAV News

  • Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity
  • Seeking Alpha - Article.5d ago
  • Aravive, AstraZeneca Report Initiation Of Randomized Phase 1/2 Study Of AVB-500 In Combo With Durvalumab In Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
  • Benzinga.11/12 14:08
  • Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
  • GlobeNewswire.11/12 13:00
  • Aravive EPS misses by $0.04
  • seekingalpha.11/08 03:11

More

Industry

Biotechnology & Medical Research
+2.06%
Pharmaceuticals & Medical Research
+0.70%

Hot Stocks

Name
Price
%Change

About ARAV

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
More

Webull offers Aravive Inc (ARAV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.